Lexicon Pharmaceuticals

LXRX

時価総額 $6.76億

Lexicon Pharmaceuticals, Inc. upgraded to Buy as multiple near-term catalysts emerge across its pipeline. LXRX anticipates NDA resubmission for ZYNQUISTA in T1D by Q4 2026, contingent on STENO1 safety data. Top-line results from the pivotal phase 3 SONATA-HCM trial for sotagliflozin in HCM are expected in Q1 2027.

He feels it's a clear buy at the current price. In his view, sotagliflozin has excellent potential to win FDA approval for a new indication.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Lexicon Pharmaceuticals NASDAQ: LXRX said it has completed enrollment in its Phase III SONATA-HCM study of sotagliflozin in hypertrophic cardiomyopathy, with topline data expected in the first quarter of 2027.

Lexicon Pharmaceuticals, Inc. (LXRX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

THE WOODLANDS, Texas, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that company management will present at three upcoming investor conferences taking place in New York, NY:

Findings presented at ESC Congress 2026 and simultaneously published in JACC: Heart Failure Findings presented at ESC Congress 2026 and simultaneously published in JACC: Heart Failure

LX9851 is a first-in-class, oral non-incretin candidate being developed by Novo Nordisk for the treatment of obesity and associated metabolic disorders

Lexicon Pharmaceuticals (LXRX) is nearing multiple potential value-transforming events for sotagliflozin, and the shares have been strong since my last update. Sotagliflozin, targeting HCM and T1D, is the primary value driver; the pivotal SONATA-HCM Phase III readout is expected in 2027, and an NDA re-filing for T1D before year-end. Regulatory and commercialization risks arguably outweigh clinical risk, especially for T1D, as the company would have to commit considerable resources to commercialization to maximize the value of sotagliflozin.

Lexicon Pharmaceuticals NASDAQ: LXRX reported a wider second-quarter loss as revenue declined sharply from the prior-year period, while the company highlighted completed enrollment in its Phase III SONATA-HCM trial and outlined plans to resubmit a new drug application for ZYNQUISTA in type 1 diabetes during the fourth quarter.